|
Mr. Little joined Halozyme in 2006 and brings to Halozyme over 30 years of general management commercial operations and finance experience in the pharmaceutical industry. From 2003 to 2006 Mr. Little was Senior Vice President Commercial Operations at Neurocrine Biosciences where he was responsible for building and managing the Company's sales and marketing functions. During his tenure Mr. Little put in place a fully integrated commercial organization including a marketing team a 200 person CNS sales force and full logistical and infrastructure support in order to initially co-detail Zoloft with Pfizer and to later launch Indiplon. From 1985 to 2003 Mr. Little was at Pharmacia Inc. where his most recent position was Group Vice President Diversified Products. His responsibilities included managing Pharmacia's Diversified Products business as well as forming a new global business unit merging pricing reimbursement and health outcomes groups to focus on current industry issues pricing and drug values. From 1999 to 2001 Mr. Little was Group Vice President Specialty Products and worldwide head of a $2.5 billion global specialty products business (Ophthalmology Endocrinology Neurology and others). Mr. Little previously held a number of positions within Pharmacia including President and Managing Director of Pharmacia in Milan Italy President of Pharmacia & UpJohn in Canada and President of Pharmacia Inc. in Canada. Prior to joining Pharmacia he held positions at Adria Laboratories and Miles Laboratories/Bayer A.G. in the U.K. Italy and the United States. Mr. Little earned his degree in economics and finance from the West London Business School Ealing Technical College. | 